Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Pelvic inflammatory disease and epithelial ovarian tumors
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Obstetrik och gynekologi. Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.ORCID-id: 0009-0005-1288-4645
2023 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)Alternativ tittel
Bäckeninflammation och epiteliala ovarialtumörer (svensk)
Abstract [en]

Background: Epithelial ovarian cancer and borderline ovarian tumors consist of several histotypes in which high-grade serous carcinoma is the most common. The majority of epithelial ovarian tumors are considered to originate in the fimbriated end of the fallopian tubes. What initiates these tumors is far from completely understood. Pelvic inflammatory disease has been proposed as a modifiable risk factor for epithelial ovarian tumors. A major cause of pelvic inflammatory disease is Chlamydia trachomatis which has been shown to have cancer-causing potential. The overall purpose of this thesis was to study associations of pelvic inflammatory disease and C. trachomatis with risk of epithelial ovarian tumors.

Methods: In a cross-sectional study (Paper I) we collected ovarian tissue and corresponding blood samples from 69 women undergoing surgery due to suspected ovarian pathology. C. trachomatis specific protein (immunohistochemistry) and C. trachomatis DNA (qPCR) in ovarian tissue were analyzed (Paper I). In a nested case-control study (Paper II) prospective blood samples from 92 women diagnosed with high-grade serous ovarian cancer were matched to four controls each for age and date of plasma sampling. C. trachomatis specific plasma antibodies were analyzed by commercial Enzyme-Linked ImmunoSorbent Assay (ELISA) and Micro-ImmunoFluorescence (MIF) (Paper I and Paper II). We performed a nationwide register-based case-control study where we included 15 072 women diagnosed with epithelial ovarian cancer (Paper III), 4782 women diagnosed with borderline ovarian tumors (Paper IV), and ten controls each matched for age and residential district. Using national Swedish registers, we retrieved data on historyof pelvic inflammatory disease and the potential confounding factors parity, educational level, previous gynecological surgery, and hormonal therapy.

Results: We found C. trachomatis DNA in ovarian tissue of eight women with ovarian carcinoma, but not in ovarian tissue from women with borderline ovarian tumors or benign disease (Paper I). The prevalence of the C. trachomatis specific protein did not differ in benign and malignant tissue (Paper I). Prevalence of C. trachomatis specific plasma antibodies was similar in cases and controls at diagnosis (Paper I) and prospectively (Paper II). A history of clinically verified pelvic inflammatory disease was associated with an increased risk of epithelial ovarian cancer overall (Paper III) and borderline ovarian tumors overall (Paper IV). Histotype-specific analyses showed an increased risk of serous carcinoma (Paper III), high-grade serous carcinoma (Paper III), clear cell carcinoma (Paper III), and serous borderline ovarian tumors (Paper IV) but not significantly with other histotypes. A dose-response relationship was seen between an increased number of pelvic inflammatory disease episodes and epithelial ovarian cancer (Paper III), as well as borderline ovarian tumors (Paper IV).

Conclusions: This thesis contributes to an improved understanding of the association between pelvic inflammatory disease and epithelial ovarian tumors. The results regarding C. trachomatis are inconclusive and suggests that the association of pelvic inflammatory disease with epithelial ovarian tumors acts through mechanisms other than Chlamydia alone.

Abstract [sv]

Bakgrund: Epitelial ovarialcancer och ovariella borderlinetumörer består av flera histotyper där höggradigt seröst karcinom är den vanligaste. Majoriteten av epiteliala ovarialtumörer anses ha sitt ursprung i äggledarnas yttersta del, men vad som initierar dessa tumörer är inte klarlagt. Bäckeninflammation har föreslagits vara en modifierbar riskfaktor. Chlamydia trachomatis har visats ha cancerframkallande egenskaper och är en viktig orsak till bäckeninflammation. Syftet med denna avhandling var att studera om C. trachomatis och bäckeninflammation har samband med risk för epiteliala ovarialtumörer.

Metod: I en tvärsnittsstudie samlades ovarialvävnad och blodprover från 69 kvinnor som genomgått operation på grund av misstänkt sjukdom i äggstocken (Studie I). C. trachomatis-specifikt protein (immunhistokemi) och C. trachomatis-DNA (qPCR) analyserades i ovarialvävnad. I en nestad fall-kontroll studie analyserades prospektiva blodprover från 92 kvinnor som diagnostiserats med höggradigt serös ovarialcancer, samt prover från fyra kontroller vardera matchade med avseende på ålder och datum för provtagning (Studie II). C. trachomatis-specifika plasmaantikroppar analyserades med hjälp av ELISA (Enzyme-Linked ImmunoSorbent Assay) och MIF-analyser (Micro-ImmunoFlourescence) (Studie I och Studie II). I en rikstäckande registerbaserad fall-kontroll studie inkluderades 15 072 kvinnor som diagnostiserats med epitelial ovarialcancer (Studie III) och 4 782 kvinnor som diagnostiserats med borderlinetumörer (Studie IV) samt tio kontroller per fall som matchades med avseende på ålder och boendedistrikt. Från nationella svenska register hämtades uppgifter om tidigare bäckeninflammation och de potentiella förväxlingsfaktorerna paritet, utbildningsnivå, tidigare gynekologisk kirurgi och hormonell behandling.

Resultat: C. trachomatis-DNA identifierades i ovarialvävnad från åtta kvinnor med ovarialcancer, men inte i ovarialvävnad från kvinnor med borderlinetumörer eller godartade ovarialtumörer. Förekomsten av det C. trachomatis-specifika proteinet skiljde sig inte åt mellan godartad, borderline eller malign vävnad. Prevalensen av C. trachomatis-specifika plasmaantikroppar var likartad hos fall och kontroller såväl vid diagnos som prospektivt. En historia av bäckeninflammation var associerad med en ökad risk för epitelial ovarialcancer och borderlinetumörer. Histotypspecifika analyser visade en ökad risk för serösa, höggradigt serösa och klarcells karcinom samt serösa borderlinetumörer men inte signifikant med andra andra histotyper. Ett dos-respons förhållande sågs för antal episoder av bäckeninflammation och risk för epitelial ovarialcancer samt borderlinetumörer.

Slutsats: Denna avhandling bidrar till en förbättrad förståelse av sambandet mellan bäckeninflammation och epiteliala ovarialtumörer. Resultaten avseende C. trachomatis är inte entydiga och tyder på att sambandet mellan bäckeninflammation och epiteliala ovarialtumörer medieras genom andra mekanismer än enbart C. trachomatis.

sted, utgiver, år, opplag, sider
Umeå: Umeå University , 2023. , s. 65
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2242
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-208116ISBN: 978-91-8070-051-1 (tryckt)ISBN: 978-91-8070-052-8 (digital)OAI: oai:DiVA.org:umu-208116DiVA, id: diva2:1755856
Disputas
2023-06-02, Hörsal B, Målpunkt T, byggnad 1D 9 trp, Norrlands universitetssjukhus, Umeå, 13:00 (svensk)
Opponent
Veileder
Forskningsfinansiär
Cancerforskningsfonden i NorrlandRegion VästerbottenUmeå UniversityTilgjengelig fra: 2023-05-12 Laget: 2023-05-09 Sist oppdatert: 2023-05-10bibliografisk kontrollert
Delarbeid
1. Chlamydia trachomatis, Chlamydial Heat Shock Protein 60 and Anti-Chlamydial Antibodies in Women with Epithelial Ovarian Tumors
Åpne denne publikasjonen i ny fane eller vindu >>Chlamydia trachomatis, Chlamydial Heat Shock Protein 60 and Anti-Chlamydial Antibodies in Women with Epithelial Ovarian Tumors
Vise andre…
2018 (engelsk)Inngår i: Translational Oncology, ISSN 1944-7124, E-ISSN 1936-5233, Vol. 11, nr 2, s. 546-551Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVE: Chlamydia trachomatis (C. trachomatis) infection has been suggested to promote epithelial ovarian cancer (EOC) development. This study sought to explore the presence of C. trachomatis DNA and chlamydial heat shock protein 60 (chsp60) in ovarian tissue, as well as anti-chlamydial IgG antibodies in plasma, in relation to subtypes of EOC. METHODS: This cross-sectional cohort consisted of 69 women who underwent surgery due to suspected ovarian pathology. Ovarian tissue and corresponding blood samples were collected at the time of diagnosis. In ovarian tumor tissue, p53, p16, Ki67 and chsp60 were analyzed immunohistochemically, and PCR was used to detect C. trachomatis DNA. Plasma C. trachomatis IgG and cHSP60 IgG were analyzed with a commercial MIF-test and ELISA, respectively. RESULTS: Eight out of 69 women had C. trachomatis DNA in their ovarian tissue, all were invasive ovarian cancer cases (16.7% of invasive EOC). The prevalence of the chsp60 protein, C. trachomatis IgG and cHSP60 IgG in HGSC, compared to other ovarian tumors, was 56.0% vs. 37.2% P = .13, 15.4% vs. 9.3% P = .46 and 63.6% vs. 45.5% P = .33 respectively. None of the markers of C. trachomatis infection were associated with p53, p16 or Ki67. CONCLUSIONS: C. trachomatis was detected in invasive ovarian cancer, supporting a possible role in carcinogenesis of EOC. However, there were no statistically significant associations of chsp60 in ovarian tissue, or plasma anti-chlamydial IgG antibodies, with any of the subtypes of ovarian tumors.

sted, utgiver, år, opplag, sider
Elsevier, 2018
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-148647 (URN)10.1016/j.tranon.2018.02.008 (DOI)000428690100041 ()29524832 (PubMedID)2-s2.0-85045732126 (Scopus ID)
Tilgjengelig fra: 2018-06-26 Laget: 2018-06-26 Sist oppdatert: 2023-05-09bibliografisk kontrollert
2. Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden
Åpne denne publikasjonen i ny fane eller vindu >>Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden
Vise andre…
2020 (engelsk)Inngår i: Translational Oncology, ISSN 1944-7124, E-ISSN 1936-5233, Vol. 13, nr 1, s. 86-91Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC.

MATERIALS AND METHODS: In a prospective nested case-control study within the Northern Sweden Health and Disease Study and the Northern Sweden Maternity Cohort, the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year before diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw, and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial micro-immunofluorescence test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique.

RESULTS: The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, P = 0.87; 27.2% vs. 28.5%, P = 0.80; median 0.24 vs. 0.25, P = 0.70). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; P < 0.001).

CONCLUSIONS: The findings of this prospective nested case-control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC.

sted, utgiver, år, opplag, sider
Elsevier, 2020
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-174272 (URN)10.1016/j.tranon.2019.09.007 (DOI)000502822300010 ()31805519 (PubMedID)2-s2.0-85075720208 (Scopus ID)
Tilgjengelig fra: 2020-08-19 Laget: 2020-08-19 Sist oppdatert: 2023-05-10bibliografisk kontrollert
3. Inflammatory disease and epithelial ovarian cancer risk: a national population-based case-control study in Sweden
Åpne denne publikasjonen i ny fane eller vindu >>Inflammatory disease and epithelial ovarian cancer risk: a national population-based case-control study in Sweden
Vise andre…
(engelsk)Manuskript (preprint) (Annet vitenskapelig)
Emneord
EOC, epithelial ovarian cancer, HGSC, high-grade serous carcinoma, ovarian cancer, pelvic inflammatory disease, PID, population-based case-control study
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-208132 (URN)
Forskningsfinansiär
Umeå University
Tilgjengelig fra: 2023-05-10 Laget: 2023-05-10 Sist oppdatert: 2023-05-10
4. Pelvic inflammatory disease and risk of borderline ovarian tumors: a national population-based case-control study in Sweden
Åpne denne publikasjonen i ny fane eller vindu >>Pelvic inflammatory disease and risk of borderline ovarian tumors: a national population-based case-control study in Sweden
Vise andre…
(engelsk)Manuskript (preprint) (Annet vitenskapelig)
Emneord
BOT, borderline ovarian tumor, serous BOT, pelvic inflammatory disease, PID, population-based case-control study
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-208135 (URN)
Forskningsfinansiär
Umeå University
Tilgjengelig fra: 2023-05-10 Laget: 2023-05-10 Sist oppdatert: 2023-05-10

Open Access i DiVA

fulltext(926 kB)403 nedlastinger
Filinformasjon
Fil FULLTEXT02.pdfFilstørrelse 926 kBChecksum SHA-512
a2b84f082182e05742a1d2afd2adfd46871b5778688093004571afdbe5ae711d8ef66a245d8c0a75b9e17318d2c24f4ce3ddcf06485df3f2b3293f44a5c64285
Type fulltextMimetype application/pdf
spikblad(151 kB)39 nedlastinger
Filinformasjon
Fil SPIKBLAD01.pdfFilstørrelse 151 kBChecksum SHA-512
eee8db03804eb470e30b25306119dc0493a5b0fba7e57a3f400659993d4459034e759c19525d005f5d615813551a55b87b332cbe586cb5e49d02ac0faf9b3bcf
Type spikbladMimetype application/pdf

Person

Jonsson, Sarah

Søk i DiVA

Av forfatter/redaktør
Jonsson, Sarah
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 404 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

isbn
urn-nbn

Altmetric

isbn
urn-nbn
Totalt: 974 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf